Chime Biologics Signs Strategic Deal with Polpharma Biologics

• Chime Biologics and Polpharma Biologics have entered a strategic agreement for end-to-end biosimilar development and manufacturing.

• The partnership aims to accelerate global market access for a biosimilar product.

Chime Biologics, a global CDMO focused on biologics, has announced a strategic cooperation agreement with Polpharma Biologics. The agreement covers the full development and manufacturing cycle of a biosimilar product intended for global markets.

Under the partnership, Chime Biologics will provide end-to-end contract manufacturing services—from investigational new drug (IND) development to commercial supply. The collaboration is designed to reduce time-to-market and enhance global access to affordable biosimilar therapies.

Polpharma Biologics is the largest biotechnology company in Poland and has a pipeline of early and late-stage biosimilars, as well as two products approved by the FDA and EMA. This agreement supports its strategy to bring European-developed biosimilars to a broader patient base by leveraging external CDMO capabilities.

Chime Biologics highlighted its cell line, process and analytical development services, expanding manufacturing capacity, and regulatory support as key assets in meeting the global demand for biosimilars. Dr. Jimmy Wei, President of Chime Biologics, said: “We are thrilled to contribute to Polpharma Biologics’ growth as we provide all-in-one solutions to accelerate biosimilar development and reduce the time-to-market.”